Related Experiment Video
Updated: May 14, 2026
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Long-term disease control of a non-operable neuroendocrine tumor of the lung with lanreotide: a case study
F Van Fraeyenhove1, E De Droogh, N Meireson
1Department of Medical Oncology, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium.
Abstract:
Bronchopulmonary neuroendocrine tumors (NETs) are malignant tumors that represent approximately 20% of all lung cancers. The therapeutic option for advanced or metastatic bronchopulmonary NETs is mainly palliation of symptoms; options need to be individualized and, therefore, rely on the knowledge of multidisciplinary teams. Somatostatin analogs have been widely used in NETs for control of hormonal syndromes and are currently under evaluation for their antiproliferative activity. Here, we present a case of NET of the lung, for which we achieved long-term disease control with a treatment comprising the somatostatin analog lanreotide Autogel(®) in a patient with limited therapeutic options due to considerable comorbidity, while preserving his quality of life.
Insights
This study shows that lanreotide Autogel, a somatostatin analog, can achieve long-term disease control for advanced lung neuroendocrine tumors (NETs). This treatment option helped preserve quality of life in a patient with significant comorbidities.
Area of Science:
- Oncology
- Endocrinology
- Pulmonology
Background:
- Bronchopulmonary neuroendocrine tumors (NETs) constitute about 20% of lung cancers.
- Treatment for advanced or metastatic lung NETs often focuses on symptom palliation and requires multidisciplinary input.
- Somatostatin analogs are established for managing hormonal syndromes in NETs and are being investigated for antiproliferative effects.
Observation:
- A case of lung NET is presented in a patient with significant comorbidities limiting therapeutic choices.
- The patient received treatment with lanreotide Autogel, a somatostatin analog formulation.
Findings:
- Long-term disease control was achieved with lanreotide Autogel.
- The treatment successfully managed the patient's condition while preserving quality of life.
Implications:
- Lanreotide Autogel offers a viable therapeutic option for advanced lung NETs in patients with limited treatment alternatives due to comorbidities.
- This case highlights the potential of somatostatin analogs beyond hormonal symptom control, suggesting antiproliferative benefits in specific clinical scenarios.
- Individualized treatment approaches, including the use of somatostatin analogs, are crucial for optimizing outcomes in complex NET cases.
